Immedica Pharma Sustainability Profile
Immedica Pharma, a prominent player in the pharmaceutical industry, is headquartered in Sweden (SE) and operates extensively across Europe and the Middle East. Founded in 2010, the company has rapidly established itself as a leader in the development and commercialisation of innovative therapies, particularly in the fields of rare diseases and specialty pharmaceuticals. Immedica Pharma is renowned for its unique portfolio of products, which includes advanced treatments that address unmet medical needs. The company’s commitment to quality and patient-centric solutions has garnered significant recognition within the healthcare community. With a strong market position, Immedica continues to expand its reach, driven by a dedication to improving patient outcomes and enhancing the quality of life for those affected by challenging health conditions.
DitchCarbon Score
How does Immedica Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Immedica Pharma's score of 44 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Immedica Pharma's reported carbon emissions
In 2023, Immedica Pharma reported total carbon emissions of approximately 2,783,000 kg CO2e, with all emissions classified under Scope 3. This figure represents a significant increase from the previous year's total of approximately 2,129,000 kg CO2e. The company has no reported emissions for Scope 1 or Scope 2, indicating that all emissions stem from upstream activities. For the Swedish operations, Immedica Pharma's total emissions were approximately 561,800 kg CO2e, comprising 158,900 kg CO2e from Scope 1, 17,480 kg CO2e from Scope 2, and 385,600 kg CO2e from Scope 3. This data highlights the company's reliance on indirect emissions, particularly in its supply chain and product distribution. Despite the emissions data, Immedica Pharma has not set specific reduction targets or initiatives as part of its climate commitments. The absence of SBTi (Science Based Targets initiative) reduction targets suggests that the company is still in the early stages of formalising its climate strategy. Overall, while Immedica Pharma has made strides in reporting its emissions, further commitments and reduction strategies will be essential for aligning with industry standards and addressing climate change effectively.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 36,700 | 00,000 |
| Scope 2 | 300 | - |
| Scope 3 | 156,101,000 | 00,000,000 |
How Carbon Intensive is Immedica Pharma's Industry?
How Carbon Intensive is Immedica Pharma's Location?
Immedica Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Immedica Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
